To date, for the response to checkpoint inhibitors, the most researched predictive biomarkers include tumor mutation burden, PD-1 expression, CD4/CD8 lymphocyte ratio, the percentage of tumor-infiltrating lymphocytes, and several methods of establishing immune scores [4–6]. This evidence concerns the gene CD4 and neoplasm.